메뉴 건너뛰기




Volumn 20, Issue 7, 2018, Pages 1100-1105

Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications

Author keywords

Antidiabetic medications; Cytokine antagonists; Heart failure with preserved ejection fraction; Sodium glucose co transporter 2 inhibitors; Statins

Indexed keywords

ANTIDIABETIC AGENT; CYCLIC AMP; EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SODIUM PROTON EXCHANGE PROTEIN 1; SODIUM PROTON EXCHANGE PROTEIN 3;

EID: 85044296571     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.1183     Document Type: Review
Times cited : (16)

References (90)
  • 1
    • 0034685403 scopus 로고    scopus 로고
    • Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    • ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000;283:1967–1975.
    • (2000) JAMA , vol.283 , pp. 1967-1975
  • 3
    • 0035810547 scopus 로고    scopus 로고
    • Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial
    • Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385–1390.
    • (2001) Lancet , vol.357 , pp. 1385-1390
    • Dargie, H.J.1
  • 4
    • 0037417252 scopus 로고    scopus 로고
    • Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
    • Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–1321.
    • (2003) N Engl J Med , vol.348 , pp. 1309-1321
    • Pitt, B.1    Remme, W.2    Zannad, F.3    Neaton, J.4    Martinez, F.5    Roniker, B.6    Bittman, R.7    Hurley, S.8    Kleiman, J.9    Gatlin, M.10
  • 5
    • 0023266532 scopus 로고
    • Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
    • CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429–1435.
    • (1987) N Engl J Med , vol.316 , pp. 1429-1435
  • 7
    • 0033517302 scopus 로고    scopus 로고
    • The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
    • Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–717.
    • (1999) N Engl J Med , vol.341 , pp. 709-717
    • Pitt, B.1    Zannad, F.2    Remme, W.J.3    Cody, R.4    Castaigne, A.5    Perez, A.6    Palensky, J.7    Wittes, J.8
  • 11
    • 33846879844 scopus 로고    scopus 로고
    • Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study
    • Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, Wenger NK. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007;115:576–583.
    • (2007) Circulation , vol.115 , pp. 576-583
    • Khush, K.K.1    Waters, D.D.2    Bittner, V.3    Deedwania, P.C.4    Kastelein, J.J.5    Lewis, S.J.6    Wenger, N.K.7
  • 13
    • 53049095795 scopus 로고    scopus 로고
    • Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
    • Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231–1239.
    • (2008) Lancet , vol.372 , pp. 1231-1239
    • Tavazzi, L.1    Maggioni, A.P.2    Marchioli, R.3    Barlera, S.4    Franzosi, M.G.5    Latini, R.6    Lucci, D.7    Nicolosi, G.L.8    Porcu, M.9    Tognoni, G.10
  • 15
    • 85021770915 scopus 로고    scopus 로고
    • Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction
    • Obokata M, Reddy YN, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017;136:6–19.
    • (2017) Circulation , vol.136 , pp. 6-19
    • Obokata, M.1    Reddy, Y.N.2    Pislaru, S.V.3    Melenovsky, V.4    Borlaug, B.A.5
  • 16
    • 84990221063 scopus 로고    scopus 로고
    • The HFpEF obesity phenotype: the elephant in the room
    • Kitzman DW, Shah SJ. The HFpEF obesity phenotype: the elephant in the room. J Am Coll Cardiol 2016;68:200–203.
    • (2016) J Am Coll Cardiol , vol.68 , pp. 200-203
    • Kitzman, D.W.1    Shah, S.J.2
  • 18
    • 85045013446 scopus 로고    scopus 로고
    • Association of hemoglobin A1c variability and the incidence of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and arterial hypertension
    • Aug 15., [Epub ahead of print]
    • Gu J, Fan YQ, Zhang JF, Wang CQ. Association of hemoglobin A1c variability and the incidence of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and arterial hypertension. Hellenic J Cardiol 2017 Aug 15. https://doi.org/10.1016/j.hjc.2017.08.001. [Epub ahead of print]
    • (2017) Hellenic J Cardiol
    • Gu, J.1    Fan, Y.Q.2    Zhang, J.F.3    Wang, C.Q.4
  • 19
    • 84954323250 scopus 로고    scopus 로고
    • The association and interaction analysis of hypertension and diabetes mellitus on diastolic heart failure in a high-risk population
    • Meng XY, Zhou Y, Zhang J, Tang ZH. The association and interaction analysis of hypertension and diabetes mellitus on diastolic heart failure in a high-risk population. Int J Clin Exp Med 2015;8:21311–21318.
    • (2015) Int J Clin Exp Med , vol.8 , pp. 21311-21318
    • Meng, X.Y.1    Zhou, Y.2    Zhang, J.3    Tang, Z.H.4
  • 20
    • 84947429178 scopus 로고    scopus 로고
    • Increased epicardial adipose tissue thickness in type 2 diabetes mellitus and obesity
    • Song DK, Hong YS, Lee H, Oh JY, Sung YA, Kim Y. Increased epicardial adipose tissue thickness in type 2 diabetes mellitus and obesity. Diabetes Metab J 2015;39:405–413.
    • (2015) Diabetes Metab J , vol.39 , pp. 405-413
    • Song, D.K.1    Hong, Y.S.2    Lee, H.3    Oh, J.Y.4    Sung, Y.A.5    Kim, Y.6
  • 22
    • 48349146146 scopus 로고    scopus 로고
    • The double role of epicardial adipose tissue as pro- and anti-inflammatory organ
    • Iacobellis G, Barbaro G. The double role of epicardial adipose tissue as pro- and anti-inflammatory organ. Horm Metab Res 2008;40:442–445.
    • (2008) Horm Metab Res , vol.40 , pp. 442-445
    • Iacobellis, G.1    Barbaro, G.2
  • 23
    • 84929966037 scopus 로고    scopus 로고
    • Local and systemic effects of the multifaceted epicardial adipose tissue depot
    • Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol 2015;11:363–371.
    • (2015) Nat Rev Endocrinol , vol.11 , pp. 363-371
    • Iacobellis, G.1
  • 26
    • 84875458263 scopus 로고    scopus 로고
    • Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning)
    • Alexopoulos N, Melek BH, Arepalli CD, Hartlage GR, Chen Z, Kim S, Stillman AE, Raggi P. Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning). J Am Coll Cardiol 2013;61:1956–1961.
    • (2013) J Am Coll Cardiol , vol.61 , pp. 1956-1961
    • Alexopoulos, N.1    Melek, B.H.2    Arepalli, C.D.3    Hartlage, G.R.4    Chen, Z.5    Kim, S.6    Stillman, A.E.7    Raggi, P.8
  • 28
    • 38749102425 scopus 로고    scopus 로고
    • Effects of atorvastatin on the different phases of atherogenesis
    • Rubba P. Effects of atorvastatin on the different phases of atherogenesis. Drugs 2007;67 Suppl 1:17–27.
    • (2007) Drugs , vol.67 , pp. 17-27
    • Rubba, P.1
  • 30
    • 78650840067 scopus 로고    scopus 로고
    • Perivascular adipose tissue as a cause of atherosclerosis
    • Verhagen SN, Visseren FL. Perivascular adipose tissue as a cause of atherosclerosis. Atherosclerosis 2011;214:3–10.
    • (2011) Atherosclerosis , vol.214 , pp. 3-10
    • Verhagen, S.N.1    Visseren, F.L.2
  • 31
    • 79151483849 scopus 로고    scopus 로고
    • Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels
    • Bot I, Jukema JW, Lankhuizen IM, van Berkel TJ, Biessen EA. Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels. Atherosclerosis 2011;214:295–300.
    • (2011) Atherosclerosis , vol.214 , pp. 295-300
    • Bot, I.1    Jukema, J.W.2    Lankhuizen, I.M.3    van Berkel, T.J.4    Biessen, E.A.5
  • 32
    • 77958487910 scopus 로고    scopus 로고
    • Association of epicardial adipose tissue with coronary atherosclerosis is region-specific and independent of conventional risk factors and intra-abdominal adiposity
    • Wang TD, Lee WJ, Shih FY, Huang CH, Chen WJ, Lee YT, Shih TT, Chen MF. Association of epicardial adipose tissue with coronary atherosclerosis is region-specific and independent of conventional risk factors and intra-abdominal adiposity. Atherosclerosis 2010;213:279–287.
    • (2010) Atherosclerosis , vol.213 , pp. 279-287
    • Wang, T.D.1    Lee, W.J.2    Shih, F.Y.3    Huang, C.H.4    Chen, W.J.5    Lee, Y.T.6    Shih, T.T.7    Chen, M.F.8
  • 35
    • 82355173484 scopus 로고    scopus 로고
    • Depot-specific overexpression of proinflammatory, redox, endothelial cell, and angiogenic genes in epicardial fat adjacent to severe stable coronary atherosclerosis
    • Sacks HS, Fain JN, Cheema P, Bahouth SW, Garrett E, Wolf RY, Wolford D, Samaha J. Depot-specific overexpression of proinflammatory, redox, endothelial cell, and angiogenic genes in epicardial fat adjacent to severe stable coronary atherosclerosis. Metab Syndr Relat Disord 2011;9:433–439.
    • (2011) Metab Syndr Relat Disord , vol.9 , pp. 433-439
    • Sacks, H.S.1    Fain, J.N.2    Cheema, P.3    Bahouth, S.W.4    Garrett, E.5    Wolf, R.Y.6    Wolford, D.7    Samaha, J.8
  • 36
    • 85026508106 scopus 로고    scopus 로고
    • Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease
    • Patel VB, Shah S, Verma S, Oudit GY. Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease. Heart Fail Rev 2017;22:889–902.
    • (2017) Heart Fail Rev , vol.22 , pp. 889-902
    • Patel, V.B.1    Shah, S.2    Verma, S.3    Oudit, G.Y.4
  • 37
    • 85031689841 scopus 로고    scopus 로고
    • ACE2/Ang 1–7 axis: a critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity
    • Patel VB, Basu R, Oudit GY. ACE2/Ang 1–7 axis: a critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity. Adipocyte 2016;5:306–311.
    • (2016) Adipocyte , vol.5 , pp. 306-311
    • Patel, V.B.1    Basu, R.2    Oudit, G.Y.3
  • 38
    • 85031406636 scopus 로고    scopus 로고
    • Evolutional change in epicardial fat and its correlation with myocardial diffuse fibrosis in heart failure patients
    • Wu CK, Tsai HY, Su MM, Wu YF, Hwang JJ, Lin JL, Lin LY, Chen JJ. Evolutional change in epicardial fat and its correlation with myocardial diffuse fibrosis in heart failure patients. J Clin Lipidol 2017;11:1421–1431.
    • (2017) J Clin Lipidol , vol.11 , pp. 1421-1431
    • Wu, C.K.1    Tsai, H.Y.2    Su, M.M.3    Wu, Y.F.4    Hwang, J.J.5    Lin, J.L.6    Lin, L.Y.7    Chen, J.J.8
  • 41
    • 85030159134 scopus 로고    scopus 로고
    • Relationships between periventricular epicardial adipose tissue accumulation, coronary microcirculation, and left ventricular diastolic dysfunction
    • Nakanishi K, Fukuda S, Tanaka A, Otsuka K, Taguchi H, Shimada K. Relationships between periventricular epicardial adipose tissue accumulation, coronary microcirculation, and left ventricular diastolic dysfunction. Can J Cardiol 2017;33:1489–1497.
    • (2017) Can J Cardiol , vol.33 , pp. 1489-1497
    • Nakanishi, K.1    Fukuda, S.2    Tanaka, A.3    Otsuka, K.4    Taguchi, H.5    Shimada, K.6
  • 43
    • 33846388449 scopus 로고    scopus 로고
    • Relationship of epicardial adipose tissue with atrial dimensions and diastolic function in morbidly obese subjects
    • Iacobellis G, Leonetti F, Singh N, Sharma AM. Relationship of epicardial adipose tissue with atrial dimensions and diastolic function in morbidly obese subjects. Int J Cardiol 2007;115:272–273.
    • (2007) Int J Cardiol , vol.115 , pp. 272-273
    • Iacobellis, G.1    Leonetti, F.2    Singh, N.3    Sharma, A.M.4
  • 44
    • 85017131584 scopus 로고    scopus 로고
    • Effects of atorvastatin treatment on left ventricular diastolic function in peritoneal dialysis patients – the ALEVENT clinical trial
    • Wu CK, Yeh CF, Chiang JY, Lin TT, Wu YF, Chiang CK, Kao TW, Hung KY, Huang JW. Effects of atorvastatin treatment on left ventricular diastolic function in peritoneal dialysis patients – the ALEVENT clinical trial. J Clin Lipidol 2017;11:657–666.
    • (2017) J Clin Lipidol , vol.11 , pp. 657-666
    • Wu, C.K.1    Yeh, C.F.2    Chiang, J.Y.3    Lin, T.T.4    Wu, Y.F.5    Chiang, C.K.6    Kao, T.W.7    Hung, K.Y.8    Huang, J.W.9
  • 45
    • 84861339380 scopus 로고    scopus 로고
    • Diastolic function parameters are improved by the addition of simvastatin to enalapril-based treatment in hypertensive individuals
    • Beck AL, Otto ME, D'Avila LB, Netto FM, Armendaris MK, Sposito AC. Diastolic function parameters are improved by the addition of simvastatin to enalapril-based treatment in hypertensive individuals. Atherosclerosis 2012;222:444–448.
    • (2012) Atherosclerosis , vol.222 , pp. 444-448
    • Beck, A.L.1    Otto, M.E.2    D'Avila, L.B.3    Netto, F.M.4    Armendaris, M.K.5    Sposito, A.C.6
  • 47
    • 85018753499 scopus 로고    scopus 로고
    • Inhibition of angiotensin II-induced cardiac fibrosis by atorvastatin in adiponectin knockout mice
    • Choi SY, Park JS, Roh MS, Kim CR, Kim MH, Serebruany V. Inhibition of angiotensin II-induced cardiac fibrosis by atorvastatin in adiponectin knockout mice. Lipids 2017;52:415–422.
    • (2017) Lipids , vol.52 , pp. 415-422
    • Choi, S.Y.1    Park, J.S.2    Roh, M.S.3    Kim, C.R.4    Kim, M.H.5    Serebruany, V.6
  • 48
    • 84903890376 scopus 로고    scopus 로고
    • Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats
    • Akahori H, Tsujino T, Naito Y, Matsumoto M, Sasaki N, Iwasaku T, Eguchi A, Sawada H, Hirotani S, Masuyama T. Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats. J Hypertens 2014;32:1534–1541.
    • (2014) J Hypertens , vol.32 , pp. 1534-1541
    • Akahori, H.1    Tsujino, T.2    Naito, Y.3    Matsumoto, M.4    Sasaki, N.5    Iwasaku, T.6    Eguchi, A.7    Sawada, H.8    Hirotani, S.9    Masuyama, T.10
  • 49
    • 84923471042 scopus 로고    scopus 로고
    • Statins beneficial for heart failure with preserved ejection fraction but not heart failure with reduced ejection fraction?
    • Ohte N, Little WC. Statins beneficial for heart failure with preserved ejection fraction but not heart failure with reduced ejection fraction? Circ J 2015;79:508–509.
    • (2015) Circ J , vol.79 , pp. 508-509
    • Ohte, N.1    Little, W.C.2
  • 50
    • 84963626029 scopus 로고    scopus 로고
    • The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses
    • Fukuta H, Goto T, Wakami K, Ohte N. The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses. Int J Cardiol 2016;214:301–306.
    • (2016) Int J Cardiol , vol.214 , pp. 301-306
    • Fukuta, H.1    Goto, T.2    Wakami, K.3    Ohte, N.4
  • 51
    • 22544443085 scopus 로고    scopus 로고
    • Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report
    • Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005;112:357–363.
    • (2005) Circulation , vol.112 , pp. 357-363
    • Fukuta, H.1    Sane, D.C.2    Brucks, S.3    Little, W.C.4
  • 52
    • 84896034713 scopus 로고    scopus 로고
    • Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction
    • Liu G, Zheng XX, Xu YL, Ru J, Hui RT, Huang XH. Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction. Am J Cardiol 2014;113:1198–1204.
    • (2014) Am J Cardiol , vol.113 , pp. 1198-1204
    • Liu, G.1    Zheng, X.X.2    Xu, Y.L.3    Ru, J.4    Hui, R.T.5    Huang, X.H.6
  • 57
    • 85031691422 scopus 로고    scopus 로고
    • Characteristics of vessels wall, myocardium and epicardial fat in patients with heart failure with preserved ejection fraction with and without metabolic syndrome
    • Zyatenkova E, Drapkina O, Ivashkin V. Characteristics of vessels wall, myocardium and epicardial fat in patients with heart failure with preserved ejection fraction with and without metabolic syndrome. Endosc Ultrasound 2014;3(Suppl 1):S1–2.
    • (2014) Endosc Ultrasound , vol.3 , pp. S1-2
    • Zyatenkova, E.1    Drapkina, O.2    Ivashkin, V.3
  • 59
    • 85039972259 scopus 로고    scopus 로고
    • Distinct myocardial targets for diabetes therapy in heart failure with preserved or reduced ejection fraction
    • Paulus WJ, Dal Canto E. Distinct myocardial targets for diabetes therapy in heart failure with preserved or reduced ejection fraction. JACC Heart Fail 2018;6:1–7.
    • (2018) JACC Heart Fail , vol.6 , pp. 1-7
    • Paulus, W.J.1    Dal, C.E.2
  • 61
    • 38349150595 scopus 로고    scopus 로고
    • Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy
    • Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51:415–426.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 415-426
    • Ramasubbu, K.1    Estep, J.2    White, D.L.3    Deswal, A.4    Mann, D.L.5
  • 62
    • 33847309058 scopus 로고    scopus 로고
    • Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure
    • Krum H, Ashton E, Reid C, Kalff V, Rogers J, Amarena J, Singh B, Tonkin A. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007;13:1–7.
    • (2007) J Card Fail , vol.13 , pp. 1-7
    • Krum, H.1    Ashton, E.2    Reid, C.3    Kalff, V.4    Rogers, J.5    Amarena, J.6    Singh, B.7    Tonkin, A.8
  • 63
    • 78951482018 scopus 로고    scopus 로고
    • Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study
    • Ashton E, Windebank E, Skiba M, Reid C, Schneider H, Rosenfeldt F, Tonkin A, Krum H. Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Int J Cardiol 2011;146:404–407.
    • (2011) Int J Cardiol , vol.146 , pp. 404-407
    • Ashton, E.1    Windebank, E.2    Skiba, M.3    Reid, C.4    Schneider, H.5    Rosenfeldt, F.6    Tonkin, A.7    Krum, H.8
  • 65
    • 0038755661 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial
    • Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133–3140.
    • (2003) Circulation , vol.107 , pp. 3133-3140
    • Chung, E.S.1    Packer, M.2    Lo, K.H.3    Fasanmade, A.A.4    Willerson, J.T.5
  • 66
    • 1242315583 scopus 로고    scopus 로고
    • Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy
    • Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305–311.
    • (2004) Am J Med , vol.116 , pp. 305-311
    • Wolfe, F.1    Michaud, K.2
  • 70
    • 77956618692 scopus 로고    scopus 로고
    • Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
    • Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010;376:886–894.
    • (2010) Lancet , vol.376 , pp. 886-894
    • Böhm, M.1    Swedberg, K.2    Komajda, M.3    Borer, J.S.4    Ford, I.5    Dubost-Brama, A.6    Lerebours, G.7    Tavazzi, L.8
  • 71
    • 85032732608 scopus 로고    scopus 로고
    • Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?
    • 627–629.
    • Packer M. Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure? Eur J Heart Fail 2018;20:627–629.
    • (2018) Eur J Heart Fail , vol.20
    • Packer, M.1
  • 77
    • 85018253813 scopus 로고    scopus 로고
    • SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor
    • Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther 2017;31:119–132.
    • (2017) Cardiovasc Drugs Ther , vol.31 , pp. 119-132
    • Ye, Y.1    Bajaj, M.2    Yang, H.C.3    Perez-Polo, J.R.4    Birnbaum, Y.5
  • 78
    • 85010842028 scopus 로고    scopus 로고
    • Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
    • Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med 2017;104:298–310.
    • (2017) Free Radic Biol Med , vol.104 , pp. 298-310
    • Lee, T.M.1    Chang, N.C.2    Lin, S.Z.3
  • 81
    • 85049506770 scopus 로고    scopus 로고
    • Identifier NCT03057951., (2 March 2018)term=empagliflozin&cond=heart+failure&rank=6
    • EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved). ClinicalTrials.gov Identifier: NCT03057951. https://clinicaltrials.gov/ct2/show/NCT03057951?term=empagliflozin&cond=heart+failure&rank=6. (2 March 2018)
  • 82
    • 85049527228 scopus 로고    scopus 로고
    • Identifier NCT03057977., (2 March,rank=5
    • EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced). ClinicalTrials.gov Identifier: NCT03057977. https://clinicaltrials.gov/ct2/show/NCT03057977?term=empagliflozin&cond=heart+failure&rank=5. (2 March 2018)
    • (2018)
  • 83
    • 85049537025 scopus 로고    scopus 로고
    • Identifier NCT03036124., (2 March,cond=heart+failure+dapagliflozin&rank=3
    • Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (Dapa-HF). ClinicalTrials.gov Identifier: NCT03036124. https://clinicaltrials.gov/ct2/show/NCT03036124?cond=heart+failure+dapagliflozin&rank=3. (2 March 2018)
    • (2018)
  • 84
    • 85032620814 scopus 로고    scopus 로고
    • Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action
    • Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2017;2:1025–1029.
    • (2017) JAMA Cardiol , vol.2 , pp. 1025-1029
    • Packer, M.1    Anker, S.D.2    Butler, J.3    Filippatos, G.4    Zannad, F.5
  • 85
    • 85031915334 scopus 로고    scopus 로고
    • Activation and inhibition of sodium–hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure
    • Packer M. Activation and inhibition of sodium–hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation 2017;136:1548–1559.
    • (2017) Circulation , vol.136 , pp. 1548-1559
    • Packer, M.1
  • 86
    • 0037015165 scopus 로고    scopus 로고
    • Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial
    • Davis BR, Cutler JA, Furberg CD, Wright JT, Farber MA, Felicetta JV, Stokes JD; ALLHAT Collaborative Research Group. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Ann Intern Med 2002;137:313–320.
    • (2002) Ann Intern Med , vol.137 , pp. 313-320
    • Davis, B.R.1    Cutler, J.A.2    Furberg, C.D.3    Wright, J.T.4    Farber, M.A.5    Felicetta, J.V.6    Stokes, J.D.7
  • 87
    • 84963691781 scopus 로고    scopus 로고
    • Heart failure with preserved ejection fraction in hypertension
    • Teo LY, Chan LL, Lam CS. Heart failure with preserved ejection fraction in hypertension. Curr Opin Cardiol 2016;31:410–416.
    • (2016) Curr Opin Cardiol , vol.31 , pp. 410-416
    • Teo, L.Y.1    Chan, L.L.2    Lam, C.S.3
  • 89
    • 84881530438 scopus 로고    scopus 로고
    • Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2)
    • Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O'Connor C, Rouleau JL, Schocken D, Anderson SA, DeMets DL; PRAISE-2 Study Group. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). JACC Heart Fail 2013;1:308–314.
    • (2013) JACC Heart Fail , vol.1 , pp. 308-314
    • Packer, M.1    Carson, P.2    Elkayam, U.3    Konstam, M.A.4    Moe, G.5    O'Connor, C.6    Rouleau, J.L.7    Schocken, D.8    Anderson, S.A.9    DeMets, D.L.10
  • 90
    • 0346730904 scopus 로고    scopus 로고
    • Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)
    • Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ; MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003;5:659–667.
    • (2003) Eur J Heart Fail , vol.5 , pp. 659-667
    • Cohn, J.N.1    Pfeffer, M.A.2    Rouleau, J.3    Sharpe, N.4    Swedberg, K.5    Straub, M.6    Wiltse, C.7    Wright, T.J.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.